Apoptosis induction by combination of drugs or a conjugated molecule associating non-steroidal anti-inflammatory and nitric oxide donor effects in medullary thyroid cancer models: Implication of the tumor suppressor p73

Thyroid Research

Volumn 8, Issue 1, 2015, Pages

  Ragot, Thierry ^a,b   Provost, Claire ^c   Prignon, Aurélie ^c   Cohen, Régis ^d   Lepoivre, Michel ^e   Lausson, Sylvie ^c  

^a France   (France)

^b CNRS   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d DELAFONTAINE HOSPITAL   (France)

^e UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Apoptosis; Medullary thyroid carcinoma; NO donors; Non steroidal anti inflammatory drugs; rMTC 6 23 cells; TT cells

Indexed keywords

CELECOXIB; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN P73;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; THYROID CANCER;

EID: 84938921134     PISSN: None     EISSN: 17566614     Source Type: Journal    
DOI: 10.1186/s13044-015-0025-3     Document Type: Article

References (37)

1. Vitale G, Caraglia M, Ciccarelli A, Lupoli G, Abbruzzese A, Tagliaferri P, et al. Current approaches and perspectives in the therapy of medullary thyroid carcinoma. Cancer. 2001;91:1797-808.
2. Pacini F, Castagna MG, Cipri C, Schlumberger M. Medullary thyroid carcinoma. Clin Oncol. 2010;22(6):475-85.
3. Cohen R, Campos J, Salaün C, Heshmati H, Kraimps J, Proye C, et al. Preoperative calcitonin levels are predictive of tumor size and postoperative calcitonin normalization in medullary thyroid carcinoma. J Clin Endocrinol Metab. 2000;85:919-22.
4. Schlumberger M, Carlomagno F, Baudin E, Bidart J, Santoro M. New therapeutic approaches to treat medullary thyroid carcinoma. Nat Clin Pract Endocrinol Metab. 2008;4:22-32.
5. Wells Jr SA, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, et al. Revised american thyroid association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015;25:567-610.
6. DuBois RN, Giardiello FM, Smalley WE. Nonsteroidal anti-inflammatory drugs, and colorectal cancer prevention. Gastroenterol Clin North Am. 1996;25:773-91.
7. Langman MJ, Cheng KK, Gilman EA, Lancashire RJ. Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. BMJ. 2000;320:1642-6.
8. Rothwell PM, Price JF, Fowkes FG, Zanchetti A, Tognoni G, Lee R, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-cardiovascular death: analysis of the time course of risks and benefits in51 randomised controlled trials. Lancet. 2012;379:1602-12.
9. Quidville V, Segond N, Pidoux E, Cohen R, Jullienne A, Lausson S. Tumor growth inhibition by indomethacin in a mouse model of human medullary thyroid cancer: implication of cyclooxygenases and 15-hydroxyprostaglandin dehydrogenase. Endocrinology. 2004;145:2561-71.
10. Quidville V, Segond N, Tebbi A, Cohen R, Jullienne A, Lepoivre M, et al. Anti-tumoral effect of a celecoxib low dose on a model of human medullary thyroid cancer in nude mice. Thyroid. 2009;19:613-21.
11. Soler MN, Bobe P, Benihoud K, Lemaire G, Roos BA, Lausson S. Gene therapy of rat medullary thyroid cancer by naked nitric oxide synthase II DNA injection. J Gene Med. 2000;2:344-52.
12. Wallace JL, Del Soldato P. The therapeutical potential of NO-NSAIDs. Fundam Clin Pharmacol. 2003;17:11-20.
13. Rao CV, Reddy BS, Steele VE, Wang CX, Liu X, Ouyang N, et al. Nitric oxide-releasing aspirin and indomethacin are potent inhibitors against colon cancer in azoxymethane-treated rats: effects on molecular targets. Mol Cancer Ther. 2006;5:1530-8.
14. Ouyang N, Williams JL, Tsioulias GJ, Gao JJ, Iatropoulos MJ, Kopelovich L, et al. Nitric oxide-donating aspirin prevents pancreatic cancer in a hamster tumor model. Cancer Res. 2006;66:4503-11.
15. Akaike T, Fujii S, Kato A, Yoshitake J, Miyamoto Y, Sawa T, et al. Viral mutation accelerated by nitric oxide production during infection in vivo. Faseb J. 2000;14:1447-54.
16. Messmer UK, Ankarcrona M, Nicotera P, Brune B. p53 expression in nitric oxide-induced apoptosis. FEBS Lett. 1994;355:23-6.
17. Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A, et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell. 1997;90:809-19.
18. Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dotsch V, et al. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell. 1998;2:305-16.
19. Muller M, Schleithoff ES, Stremmel W, Melino G, Krammer PH, Schilling T. One, two, three - p53, p63, p73 and chemosensitivity. Drug Resist Updat. 2006;9:288-306.
20. Tebbi A, Guittet O, Cottet MH, Vésin F, Lepoivre M. TAp73 induction by nitric oxide. JBC. 2011;286:7873-84.
21. Guittet O, Tebbi A, Cottet MH, Vesin F, Lepoivre M. Upregulation of the p53R2 ribonucleotide reductase subunit by nitric oxide. Nitric Oxide. 2008;19:84-94.
22. Bressenot A, Marchal S, Bezdetnaya L, Garrier J, Guillemin F, Plénat F. Assessment of apoptosis by immunohistochemistry to active caspase-3, active caspase-7, or cleaved PARP in monolayer cells and spheroid and subcutaneous xenografts of human carcinoma. J Histochem Cytochem. 2009;57:289-300.
23. Kashfi K, Ryan Y, Qiao LL, Williams JL, Chen J, Del Soldato P, et al. Nitric oxide-donating non-steroidal anti-inflammatory drugs inhibit the growth of various cultured human cancer cells: evidence of a tissue type-independent effect. J Pharmacol Exp Ther. 2002;303:1273-82.
24. Huguenin S, Fleury-Feith J, Kheuang L, Jaurand MC, Bolla M, Riffaud JP, et al. Nitrosulindac (NCX 1102): a new nitric oxide- donating non steroidal anti-inflammatory drug (NO-NSAID), inhibits proliferation and induces apoptosis in human prostatic epithelial cell lines. Prostate. 2004;61:132-41.
25. Huguenin S, Vacherot F, Kheuang L, Fleury-Feith J, Jaurand MC, Bolla M, et al. Antiproliferative effect of nitrosulindac (NCX 1102), a new nitric oxide- donating non steroidal anti-inflammatory drug, on human bladder carcinoma cell lines. Mol Cancer Ther. 2004;3:291-8.
26. Fabbri F, Brigliadori G, Ulivi P, Tesei A, Vannini I, Rosetti M, et al. Pro-apototic effect of nitric oxide- donating NSAID, NCX 4040, on bladder carcinoma cells. Apoptosis. 2005;10:1095-103.
27. Bozzo F, Bassignana A, Lazzarato L, Boschi D, Gasco A, Bocca C, et al. Novel nitro-oxy derivatives of celecoxib for the regulation of colon cancer cell growth. Chem Biol Interact. 2009;182(2-3):183-90.
28. Bocca C, Bozzo F, Bassignana A, Miglietta A. Antiproliferative effects of COX-2 inhibitor celecoxib on human breast cancer cell lines. Mol Cell Biochem. 2011;350:59-70.
29. Tomoda C, Moatamed F, Naeim F, Hershman JM, Sugawara M. Indomethacin inhibits cell growth of medullary thyroid carcinoma by reducing cell cycle progression into S phase. Exp Biol Med. 2008;233:1433-40.
30. Kashfi K, Rigas B. Non-COX-2 targets and cancer: expanding the molecular target repertoire of chemoprevention. Biochem Pharmacol. 2005;70:969-86.
31. Grösch S, Maier T, Schiffmann S, Geisslinger G. Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst. 2006;98:736-47.
32. Lau L, Hansford LM, Cheng LS, Hang M, Baruchel S, Kaplan DR. Cyclooxygenase inhibition modulate the p53/HDM2 pathway and enhance chemotherapy-induced apoptosis in neuroblastoma. Oncogene. 2007;26:1920-31.
33. Herfarth KKF, Wick MR, Marshall HN, Gartner E, Lum S, Moley JF. Absence of TP53 alterations in pheochromocytomas and medullary thyroid carcinomas. Genes Chromosom Cancer. 1997;20:24-9.
34. Lau LMS, Wolter JK, Lau JTML, Cheng LS, Smith KM, Hansford LM, et al. Cyclooxygenase inhibitors differentially modulate p73 isoforms in neuroblastoma. Oncogene. 2009;28:2024-33.
35. Gonzalez S, Perez-Perez MM, Hernando E, Serrano M, Cordon-Cardo C. P73beta-mediated apoptosis requires p57kip2 induction and IEX-1 inhibition. Cancer Res. 2005;65:2186-92.
36. Broutin S, Commo F, De Koning L, Marty-Prouvost B, Lacroix L, Talbot M, et al. Changes in signaling pathways induced by vandetanib in a human medullary thyroid carcinoma model, as analyzed by reverse phase protein array. Thyroid. 2014;24:43-51.
37. Sugawara M, Ly T, Hershman JM. Medullary Thyroid cancer current treatment strategy, novel therapies and perspectives for the Future. Horm Cancer. 2012;3:218-26.